BIOMAT Database Logo BIOMAT Database Logo

Generation of lymphokine-activated killer (LAK) cells and possible implications in autologous bone marrow transplantation--a preliminary report. 1990

C H Tzeng, and M W Chuang, and S Y Wang, and R K Hsieh, and C J Liu, and S Fan, and P M Chen
Department of Medicine, Veterans General Hospital, Republic of China.

Lymphokine-activated killer (LAK) cells were generated successfully without mitogen from blood mononuclear cells obtained from 14 patients with varying malignancies and 2 normal donors. Cells from both groups showed a positive cytotoxicity by a 4-hour 51-Cr-release assay against a variety of target cells including natural killer (NK) sensitive K562 myeloid leukemia, NK-resistant Raji lymphoma cell lines, and fresh/cryopreserved leukemia cells from patients refractory to standard chemotherapy but not normal blood cells. Higher cytotoxic activity was obtained with a higher effector:target ratio at 100:1 greater than 50:1 greater than 25:1 (P less than 0.01) in each setting of different targets. Experiments involving cocultures of the LAK cells with either allogeneic (9) or autologous (3) bone marrow cells disclosed no detrimental effect on the committed hemopoietic stem cells by semisolid agar colony forming unit (CFU-GM) assay. The findings suggest that LAK cells may have a potential role for the in vitro purging of the residual leukemic cells from the marrow inoculum prepared for autologous bone marrow transplantation.

UI MeSH Term Description Entries
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D007700 Kinetics The rate dynamics in chemical or physical systems.
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008223 Lymphoma A general term for various neoplastic diseases of the lymphoid tissue. Germinoblastoma,Lymphoma, Malignant,Reticulolymphosarcoma,Sarcoma, Germinoblastic,Germinoblastic Sarcoma,Germinoblastic Sarcomas,Germinoblastomas,Lymphomas,Lymphomas, Malignant,Malignant Lymphoma,Malignant Lymphomas,Reticulolymphosarcomas,Sarcomas, Germinoblastic
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

C H Tzeng, and M W Chuang, and S Y Wang, and R K Hsieh, and C J Liu, and S Fan, and P M Chen
Lymphokine-activated killer (LAK) cell purging of bone marrow.
January 1990, Progress in clinical and biological research,
C H Tzeng, and M W Chuang, and S Y Wang, and R K Hsieh, and C J Liu, and S Fan, and P M Chen
Lymphokine-activated killer cells in rats: generation of natural killer cells and lymphokine-activated killer cells from bone marrow progenitor cells.
February 1989, Cellular immunology,
C H Tzeng, and M W Chuang, and S Y Wang, and R K Hsieh, and C J Liu, and S Fan, and P M Chen
Human lymphokine activated killer (LAK) cells suppress generation of allospecific cytotoxic T cells: implications for use of LAK cells to prevent graft-versus-host disease in allogeneic bone marrow transplantation.
January 1992, Blood,
C H Tzeng, and M W Chuang, and S Y Wang, and R K Hsieh, and C J Liu, and S Fan, and P M Chen
In vitro LAK (lymphokine activated killer) activity following autologous peripheral blood stem cell is significantly greater than that following autologous bone marrow and allogeneic bone marrow transplantation.
August 1995, Bone marrow transplantation,
C H Tzeng, and M W Chuang, and S Y Wang, and R K Hsieh, and C J Liu, and S Fan, and P M Chen
Lymphokine-activated killer cells in autologous bone marrow transplantation. Evidence against inhibition of engraftment in vivo.
December 1992, Transplantation,
C H Tzeng, and M W Chuang, and S Y Wang, and R K Hsieh, and C J Liu, and S Fan, and P M Chen
Autologous bone marrow purging by lymphokine-activated killer cells: rationale and prospects.
January 1988, Pathology and immunopathology research,
C H Tzeng, and M W Chuang, and S Y Wang, and R K Hsieh, and C J Liu, and S Fan, and P M Chen
Analysis of lymphokine-activated killer (LAK) cells.
January 1987, Progress in clinical and biological research,
C H Tzeng, and M W Chuang, and S Y Wang, and R K Hsieh, and C J Liu, and S Fan, and P M Chen
Generation of lymphokine-activated killer (LAK) cells from tumor-infiltrating lymphocytes.
June 1986, Cellular immunology,
C H Tzeng, and M W Chuang, and S Y Wang, and R K Hsieh, and C J Liu, and S Fan, and P M Chen
Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies.
October 1989, Cancer research,
C H Tzeng, and M W Chuang, and S Y Wang, and R K Hsieh, and C J Liu, and S Fan, and P M Chen
Adherent lymphokine-activated killer cells suppress autologous human normal bone marrow progenitors.
June 1991, Blood,
Copied contents to your clipboard!